文献速递眼底病与葡萄膜炎

替尔泊肽与降低糖尿病视网膜病变及相关并发症风险:美国多中心队列研究

Tirzepatide and Reduced Risk of Diabetic Retinopathy and Related Complications: A Multicenter US Cohort Study.
PubMed 文献 · Ophthalmology · 2026-01-21

本研究基于TriNetX美国协作网络,比较替尔泊肽与单纯生活方式干预的糖尿病患者在糖尿病视网膜病变(DR)诊断、进展及眼部干预需求上的风险。

要点

  • 替尔泊肽与12个月内DR发生和进展风险降低相关。
  • 替尔泊肽组需抗VEGF注射和全视网膜光凝的风险显著低于对照组。
  • 结果提示替尔泊肽可能影响DR风险患者的治疗选择。

核心结论

  • 替尔泊肽与较低的DR新发或进展发生率及较少并发症相关,包括需干预的并发症。

研究设计与样本

  • 基于TriNetX美国协作网络的人群回顾性队列研究。

主要发现

  • 替尔泊肽组12个月发生轻度非增殖性DR的风险比为0.864(95%CI 0.758-0.985)。
  • 替尔泊肽组12个月发生增殖性DR的风险比为0.705(95%CI 0.564-0.882)。
  • 替尔泊肽组12个月发生DR伴黄斑水肿的风险比为0.624(95%CI 0.536-0.727)。
  • 替尔泊肽组12个月发生玻璃体积血的风险比为0.607(95%CI 0.429-0.860)。
  • 替尔泊肽组12个月发生牵拉性视网膜脱离的风险比为0.370(95%CI 0.179-0.765)。

关键数值与推荐

  • 替尔泊肽组12个月需玻璃体腔抗VEGF注射的风险比为0.479(95%CI 0.368-0.625)。
  • 替尔泊肽组12个月需全视网膜光凝的风险比为0.610(95%CI 0.403-0.924)。

临床怎么用

  • 对于糖尿病合并超重或肥胖的患者,替尔泊肽可能降低DR发生和进展风险,可作为治疗选择参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Tirzepatide, recently Food and Drug Administration (FDA) approved for weight loss, offers substantial metabolic benefits, yet its long-term impact on diabetic retinopathy (DR) remains unclear. The study purpose was to compare the risk of DR diagnoses, progression, and need for ocular interventions between patients using tirzepatide and matched patients receiving lifestyle intervention alone. DESIGN: Population-based, retrospective cohort study using the TriNetX US Collaborative Network. PARTICIPANTS: Patients with diabetes and overweight or obesity who initiated tirzepatide were included. Each tirzepatide patient was propensity score matched to a similar patient who received lifestyle intervention alone and had no exposure to weight-loss drugs. METHODS: Initiation of tirzepatide. MAIN OUTCOME MEASURES: Onset of DR, progression to more severe stages of DR, or need for interventions, such as intravitreal anti-VEGF injection and pan-retinal photocoagulation. RESULTS: After propensity matching for demographic, metabolic, and systemic covariates, 173 846 patients were included in the analysis (86 923 per cohort; mean [standard deviation] age, 56.9 [12.7] years; 86 740 [52.0%] women). Tirzepatide use was associated with reduced 12-month risk of DR incidence and worsening events than the lifestyle intervention alone cohort, including incident mild nonproliferative diabetic retinopathy (NPDR) (risk ratio [RR], 0.864 [95% confidence interval {CI}, 0.758-0.985], proliferative diabetic retinopathy (PDR) (RR, 0.705 [0.564-0.882]), DR with macular edema (RR, 0.624 [0.536-0.727], vitreous hemorrhage (RR, 0.607 [0.429-0.860]), tractional retinal detachment (RR, 0.370 [0.179-0.765], intravitreal anti-VEGF injection (RR, 0.479 [0.368-0.625]), and pan-retinal photocoagulation (RR, 0.610 [0.403-0.924]). CONCLUSIONS: Tirzepatide was associated with a lower incidence of new or progressive DR and fewer complications, including those requiring interventions, compared with lifestyle intervention alone. These findings may inform treatment selection for patients at risk for DR. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Shah J, Razavi P, Festok M, et al. Tirzepatide and Reduced Risk of Diabetic Retinopathy and Related Complications: A Multicenter US Cohort Study. Ophthalmology. 2026. PMID: 41577258. doi:10.1016/j.ophtha.2026.01.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。